Regenerative Medicine (Bone and Joint) Market Size to Exceed USD 21.3 Bn by 2033

The Regenerative Medicine (Bone and Joint) Market, estimated at USD 10.3 Bn in 2026, is expected to exhibit a CAGR of 11% and reach USD 21.3 Bn by 2033.

The market growth is fueled by rising demand for advanced biotechnology solutions that improve healthcare outcomes, along with increasing adoption in areas such as drug development, diagnostics, and personalized medicine. Innovations in genomics, cell and gene therapies, and biomanufacturing, supported by strong R&D investments, are enhancing treatment effectiveness, efficiency, and accessibility. Furthermore, favorable regulatory support, strategic collaborations, and the growing focus on precision medicine are accelerating market expansion and opening new opportunities for industry participants.

Global regenerative medicine (bone and joint) market is expected to witness significant growth as key companies focus on regulatory clearances and launches of advanced bone-regeneration products. For instance, on May 26, 2026, the U.S. FDA granted 510(k) clearance to SDIP Innovations’ JAZBI Resorbable Bone Void Filler, an osteoconductive, porous calcium-phosphate implant intended for bony voids or defects in the extremities and pelvis. The product gradually resorbs and is replaced by new bone during the natural healing process.

Moreover, on July 6, 2026, OSSIO announced the launch of the OSSIOfiber Interference Screw, a metal-free, bio-integrative fixation solution designed primarily for anterior cruciate ligament reconstruction. The implant provides graft fixation and is designed to integrate into the patient’s native bone, thereby avoiding permanent hardware or residual implant material. (Source: U.S.FDA; OSSIO)

Market Opportunity

• Rising Burden of Osteoarthritis and Age-Related Joint Damage

The increasing prevalence of osteoarthritis is expanding the patient pool requiring cartilage and bone-restoration treatments. The World Health Organization estimated that approximately 528 million people worldwide were living with osteoarthritis in 2019, with about 73% of patients aged over 55 years. Aging, obesity, repetitive joint stress and previous injuries further increase cartilage degeneration, supporting demand for regenerative therapies that can repair damaged tissue and delay joint replacement.

Moreover, in April 2026, the University of Colorado reported that an ARPA-H-supported project was advancing regenerative treatments designed to restore damaged cartilage and subchondral bone in osteoarthritis. (Source: WHO; University of Colorado)

• Scientific Progress in Cell-Free and Molecular Regeneration

Cell-free approaches involving exosomes, extracellular vesicles, small-molecule inhibitors and growth-factor delivery may provide easier manufacturing, storage and administration than living-cell therapies. These approaches are broadening the regenerative medicine pipeline and could reduce some of the cost, consistency and regulatory challenges associated with cell transplantation.

For instance, a June 2026 peer-reviewed study evaluated the combined use of mesenchymal stem cells and exosomes for synergistic cartilage and bone regeneration. Stanford Medicine also reported in June 2026 that inhibition of the enzyme 15-PGDH had reversed age-related cartilage loss and prevented post-injury osteoarthritis in animal studies.

To know the latest trends and insights prevalent in the Global Regenerative Medicine (Bone and Joint) Market, click the link below:

https://www.coherentmarketinsights.com/market-insight/orthopedic-regenerative-medicine-market-3566

The global regenerative medicine (bone and joint) market is also expected to witness potential growth, owing to increasing focus on gene therapy for bone regeneration. For instance, the European Union’s Horizon 2020 research and innovation program launched cmRNAbone, a novel gene therapy for bone regeneration project in January 2020. The project aims to develop a novel bone regenerative therapy for trauma and osteoporosis patients.  The researchers planned to develop chemically modified RNAs and a specific vector delivery system to be in a biomaterial formulation tailored to patients’ needs.

Global Regenerative Medicine (Bone and Joint) Market Trends

• Development of collagen- and hyaluronic-acid-based joint therapies: Biomaterial combinations are being investigated to stimulate cartilage regeneration while improving joint lubrication and clinical symptoms. For instance, in July 2026, ClinicalTrials.gov listed a study comparing collagen-polyvinylpyrrolidone with Hylan G-F 20 in patients with knee osteoarthritis, indicating continued development of injectable collagen and hyaluronic-acid-based regenerative approaches.
• Stronger standardization of regenerative biomaterials: Regulators are increasingly emphasizing standardized characterization and testing of scaffold materials to ensure consistent quality and safety. For instance, in May 2026, the U.S. FDA recognized ASTM F2064-25, covering the characterization and testing of alginates used as starting materials in biomedical and tissue-engineered products. This supports more standardized development of hydrogels, scaffolds and cell-delivery platforms.
• Advancement of stem-cell therapies into late-stage trials: Allogeneic stem-cell products are progressing from early clinical research into pivotal studies for cartilage repair. For instance, in 2026, ClinicalTrials.gov listed a Phase III study evaluating MEDIPOST’s CARTISTEM, an umbilical-cord-blood-derived mesenchymal stem-cell therapy, against surgical debridement in patients with knee cartilage lesions and osteoarthritis. The study evaluates pain, knee function and potential disease-modifying effects using MRI assessments.
• Growing use of synthetic and resorbable bone-graft materials: Calcium-phosphate-based substitutes are gaining regulatory acceptance owing to their osteoconductivity, biocompatibility and ability to be gradually replaced by natural bone. For instance, on March 6, 2026, the U.S. FDA cleared HUDENS BIO’s BONTREE PLUS, a synthetic bone-graft substitute containing hydroxyapatite and octacalcium phosphate for periodontal and oral or maxillofacial bone defects.
• Increasing adoption of metal-free, bio-integrative implants: Orthopedic fixation is shifting from permanent metallic implants toward materials that integrate with newly formed bone. For instance, in June 2026, OSSIO entered an exclusive distribution agreement with OrthoPediatrics to expand OSSIOfiber implants across approximately 400 U.S. children’s hospitals and care facilities. The mineral-fiber implants are designed to integrate into bone within 18–24 months and can reduce the need for hardware-removal surgery.
• Structural scaffolds becoming a priority technology platform: Biomaterial scaffolds that provide mechanical support while encouraging cell attachment, tissue formation and controlled biodegradation are receiving greater attention. Canada’s Drug Agency identified structural scaffolds and biomaterials among the five regenerative-medicine technology platforms to watch in its April 2026 horizon-scanning report, alongside stem-cell and gene-therapy approaches.

Key Development

• In May 6, 2026, Xtant Medical commercially launched Trivium Shaped, an advanced composite allograft offered in ready-to-use boat and strip configurations. The regenerative bone graft combines cortical fibres, cancellous bone and demineralized bone matrix. Its proprietary PureLoc technology produces elongated, uniform cortical fibres, while the pre-shaped design improves graft preparation, handling and placement during spinal and orthopedic procedures. (Source: Xtant Medical commercially)
• In April 2026, the U.S. Advanced Research Projects Agency for Health reported that its NITRO program successfully regenerated cartilage and bone in osteoarthritis animal models. Innovations include sustained-release injectable treatments, engineered protein scaffolds and a living 3D-printed knee implant seeded with human cells. The selected teams are conducting IND-enabling studies in preparation for first-in-human clinical trials.
• On May 14, 2026, MEDIPOST announced that CARTISTEM, an allogeneic umbilical-cord-blood-derived mesenchymal stem-cell therapy, met all primary and secondary efficacy endpoints in its Japanese Phase III knee osteoarthritis trial. The treatment demonstrated statistically significant improvements in pain, joint function and cartilage regeneration compared with hyaluronic-acid therapy. MEDIPOST plans to submit a Japanese biologics licence application during the second half of 2026.

Key Takeaways of the Global Regenerative Medicine (Bone and Joint) Market

• The global regenerative medicine (bone and joint) market is expected to exhibit a CAGR of 11% over the forecast period, owing to high prevalence of rheumatoid arthritis globally. For instance, according to a peer-reviewed review published in Current Opinion in Rheumatology in 2026, rheumatoid arthritis affects an estimated 17.6 million people worldwide, with its global prevalence continuing to increase. The underlying Global Burden of Disease analysis reported an age-standardized prevalence rate of 208.8 cases per 100,000 population, representing a 14.1% increase between 1990 and 2020.
• Biomaterial segment is expected to hold a dominant position in the regenerative medicine (bone and joint) market in 2026, owing to owing to increasing regulatory clearances for bioactive and resorbable bone-repair materials. For instance, in April 2026, the U.S. FDA granted 510(k) clearance to Stryker Spine’s Vitoss family of bioactive bone graft substitutes, classified as resorbable calcium-salt bone void fillers. These biomaterial scaffolds are used to fill skeletal voids or gaps in the extremities, pelvis and spine and are designed to gradually resorb and be replaced by newly formed bone during the healing process. (Source: U.S.FDA)
• Bone graft substitutes segment is expected to hold dominant position in the regenerative medicine (bone and joint) market in 2026, owing to the increasing development and regulatory clearance of advanced bioactive and resorbable bone-graft products. For instance, on April 24, 2026, the U.S. FDA granted 510(k) clearance to Stryker Spine’s Vitoss family of bioactive bone graft substitutes, including Vitoss BiModal, Vitoss BBTrauma, Vitoss BA2X and Vitoss Bioactive Foam. These products are intended to fill skeletal bone voids or gaps in the extremities, pelvis and spine. Following implantation, the scaffold gradually resorbs and is replaced by newly formed bone during the healing process.
• Key players operating in the global regenerative medicine (Bone and Joint) market include Anika Therapeutics, Inc, Arthrex, Inc., Baxter International, Inc., CONMED Corporation, Johnson & Johnson, Medtronic, Plc, Smith & Nephew plc, Stryker Corporation, Zimmer Holdings, Inc., Aziyo Biologics, and Ortho Regenerative Technologies Inc